- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.08. | AbbVie/Genmab's lymphoma drug shows promise in phase 3 combination trial | ||
| 20.08. | FDA approves Jazz Pharmaceuticals' Modeyso as first drug for ultra-rare brain cancer | ||
| 20.08. | Empathy is not a soft skill - it's a strategic one | ||
| 19.08. | Sanofi's multiple myeloma candidate granted FDA orphan drug designation | ||
| 19.08. | Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis | ||
| 19.08. | Are botanical drugs part of the future of medicine? | ||
| 18.08. | Gilead Sciences' Biktarvy granted FDA approval for expanded HIV use | ||
| 18.08. | FDA approves Apellis' Empaveli for two rare kidney diseases | ||
| 18.08. | Trust and trends - proactive protection | ||
| 15.08. | Eli Lilly's Alzheimer's drug Kisunla shows growing benefit in long-term study | ||
| 15.08. | BMS granted FDA priority review for Breyanzi in marginal zone lymphoma | ||
| 15.08. | Improving transparency and traceability within the supply chain's first mile | ||
| 14.08. | Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours | ||
| 14.08. | FDA approves PTC Therapeutics' Sephience to treat rare metabolic disorder PKU | ||
| 14.08. | Motivating low-performance teams | ||
| 13.08. | GSK and Hengrui enter multi-programme collaboration agreement worth $12bn | ||
| 13.08. | AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata | ||
| 13.08. | Celebrating the Cannes Lions International Festival of Creativity | ||
| 12.08. | Novo Nordisk's Alhemo approved by FDA for expanded haemophilia use | ||
| 12.08. | Biogen/Eisai's Alzheimer's drug Leqembi shows continued benefit over four years | ||
| 12.08. | Embracing uncertainty in precision medicine communications for lung cancer | ||
| 11.08. | FDA unveils PreCheck programme to enhance US domestic pharma supply chain | ||
| 11.08. | Eli Lilly's Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients | ||
| 11.08. | Patient activation: time to think differently about treatments… | ||
| 08.08. | MSD receives NICE recommendation for Keytruda in advanced endometrial cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .